CULTURED CILIATED CELLS FOR HIGH THROUGHPUT SCREENING

用于高通量筛选的培养纤毛细胞

• 批准号: 6691898
• 负责人: Hua Mao
• 金额: $ 37.97万
• 依托单位: BIOTECHPLEX CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6691898
• 关键词: animal tissue; biological signal transduction; biomarker; cell differentiation; cell growth regulation; cilium; cilium /flagellum motility; dogs; growth factor; high throughput technology; laboratory rabbit; laboratory rat; respiratory epithelium; technology /technique development; tissue /cell culture; tissue resource /registry; trachea

DESCRIPTION (provided by applicant): BioTechPlex proposes to develop mammalian tracheal/bronchial airway epithelial cell line, CILSCREEN TM, specifically for high throughput screening. This is based on physiological functional assays. BioTechPlex has accomplished all the proposed Phase I objectives. A) Successfully developed techniques to culture and numerically expand airway epithelial cells while preserving ciliogenesis and ciliary function. B) Developed methodologies to reactivate mechanisms of ciliogenesis to regenerate the cilia following loss of cilia induced by submerged culture. C) Developed methodologies to induce cell polarization so as to induce cilia outgrowth on more than 50 percent of epithelial cells, which maintained normal ciliary beating for at least 3-4 weeks. In this Phase II project, BioTechPlex will incorporate and extend the accomplishments of Phase I to produce viable commercial cell lines in five species to form the first Mammalian Ciliated Cell Bank. Specifically, BioTechPlex will accomplish the following objectives. 1). Further identify factors regulating cell division and differentiation. 2). Produce large quantities of airway epithelial ciliated cells. 3). Characterize the cell lines using biomarkers, morphological characteristics and physiological function, and 4). Establish a Mammalian Ciliated Cell Bank. BioTechPlex plans to facilitate widespread use of airway ciliated epithelial cells for cell function studies, i.e. the cells will become an alternative to the use of fibroblasts, tumor cell lines and other genetically altered cell lines utilized in high throughput screening for pulmonary drug discovery. These cell model systems will be suitable for the study of normal and induced pathological mechanisms and their related pharmacology.

描述（由申请人提供）：BioTechcraft拟开发哺乳动物气管/支气管气道上皮细胞系CILSCREEN TM，专门用于高通量筛选。这是基于生理功能测定。生物技术公司已经完成了所有拟议的第一阶段目标。A）成功开发了培养和数字扩增气道上皮细胞同时保留纤毛发生和纤毛功能的技术。B）开发了重新激活纤毛发生机制的方法，以在由浸没培养诱导的纤毛损失后再生纤毛。C）开发了诱导细胞极化的方法，从而在超过50%的上皮细胞上诱导纤毛生长，其维持正常纤毛搏动至少3-4周。在这个第二阶段项目中，生物技术公司将结合和扩展第一阶段的成就，在五个物种中生产可行的商业细胞系，形成第一个哺乳动物纤毛细胞库。具体而言，生物技术公司将实现以下目标。1）。进一步确定调节细胞分裂和分化的因素。2）。产生大量气道上皮纤毛细胞。3）。使用生物标志物、形态特征和生理功能表征细胞系，以及4）。建立哺乳动物纤毛细胞库。生物技术公司计划促进气道纤毛上皮细胞在细胞功能研究中的广泛使用，即这些细胞将成为在肺部药物发现的高通量筛选中使用成纤维细胞、肿瘤细胞系和其他遗传改变的细胞系的替代品。这些细胞模型系统将适用于正常和诱导的病理机制及其相关药理学的研究。